Cyclopharm (ASX:CYC) Current Accrued Expense : A$0.00 Mil (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Current Accrued Expense?

Cyclopharm's Current Accrued Expense for the quarter that ended in Jun. 2024 was A$0.00 Mil.

Cyclopharm Current Accrued Expense Historical Data

The historical data trend for Cyclopharm's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Current Accrued Expense Chart

Cyclopharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

Cyclopharm Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Cyclopharm Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Cyclopharm Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm Headlines

No Headlines